

Amendments

In the Claims

Please amend the claims as indicated below. This version of the claims will replace all prior versions.

1. (currently amended) A method for inhibiting breast tumor growth in a mammal comprising the steps of administering to the mammal:
anti-endoglin antibody SN6j or antigen binding fragment thereof; and
a chemotherapeutic agent selected from the group consisting of
cyclophosphamide (CPA) or doxorubicin,
wherein the combination of the anti-endoglin antibody SN6j or antigen binding fragment thereof and the chemotherapeutic agent has a synergistic effect on the inhibition of breast tumor growth.
- 2.-4. (canceled)
5. (original) The method of claim 1, wherein the antigen binding fragment is selected from the group consisting of F(ab')₂, Fab', Fab, Fv, Fd', Fd, single chain Fv and derivatives of single chain Fv fragments.
6. (previously amended) The method of claim 1, wherein the anti-endoglin antibody SN6j and the chemotherapeutic agent are administered sequentially.
7. (previously amended) The method of claim 1, wherein the anti-endoglin antibody SN6j and the chemotherapeutic agent are administered simultaneously.
8. (canceled)

9. (previously amended) The method of claim 1, wherein the chemotherapeutic agent is cyclophosphamide.

10. (previously amended) The method of claim 1, wherein the chemotherapeutic agent is doxorubicin.

11. (currently amended) A method for inhibiting breast tumor growth in a mammal comprising the steps of administering to the mammal:

an anti-endoglin antibody which binds to the same epitope as SN6j or an antigen binding fragment of the anti-endoglin antibody; and

a chemotherapeutic agent selected from the group consisting of cyclophosphamide and doxorubicin

wherein the combination of the anti-endoglin antibody or antigen binding fragment thereof and the chemotherapeutic agent has a synergistic effect on the inhibition of breast tumor growth.

12. (original) The method of claim 11 wherein the chemotherapeutic agent is cyclophosphamide.

13. (original) The method of claim 11 wherein the chemotherapeutic agent is doxorubicin.